Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

regeneration

  • Home
  •  
  • regeneration



  • Most Read
  • Latest Comments
  • Orthocell on commercialisation path following revolutionary tendon regeneration trials
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Orthocell on commercialisation path following revolutionary tendon regeneration trials
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Orthocell on commercialisation path following revolutionary tendon regeneration trials
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Orthocell on commercialisation path following revolutionary tendon regeneration trials
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Orthocell on commercialisation path following revolutionary tendon regeneration trials
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    Damaged nerves? Soft tissue regeneration can do a better job than sutures, says Orthocell
    • News

  • Understanding the importance of clinical trials when investing in medical research driven biotech
    Understanding the importance of clinical trials when investing in medical research driven biotech
    • Explainers

  • OrthoATI trials bring positive results for rotator cuff tendonitis patients, eyes US market
    OrthoATI trials bring positive results for rotator cuff tendonitis patients, eyes US market
    • News

  • Why Orthocell has blown my mind this morning
    Why Orthocell has blown my mind this morning
    • Opinion

  • Pharmaxis reports progress in clinical trials despite COVID affecting industry
    Pharmaxis reports progress in clinical trials despite COVID affecting industry
    • News

  • Orthocell on commercialisation path following revolutionary tendon regeneration trials
    • News

    Orthocell on commercialisation path following revolutionary tendon regeneration trials

    Labourers and athletes prone to shoulder injuries could have a significant solution after 89% of patients participating in Orthocell’s (ASX: OCC) tendon regeneration clinical trials, reported a pain-free return to work and recreation.  The remaining 11% reported improved mobility and notably, none of the trial participants require further surgery two years on from the initial

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.